BioCentury
ARTICLE | Clinical News

Bayer reports Phase II data for PI3K inhibitor copanlisib in DLBCL

June 15, 2017 8:44 PM UTC

Bayer AG (Xetra:BAYN) reported data from a Phase II trial in 67 patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who received ≥1 prior therapy showing that 60 mg IV copanlisib (BAY 80-6946) on days 1, 8 and 15 of each 28-day cycle led to an objective response rate (ORR) of 19%. In 40 evaluable patients who received ≥3 doses of copanlisib, copanlisib led to an ORR of 25%, including 5 complete responses and 5 partial responses, plus 12 cases of stable disease. Data were presented at the International Conference on Malignant Lymphoma in Lugano.

The open-label, international trial is evaluating ORR as its primary endpoint. Secondary endpoints include duration of response, progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of stable disease and safety...

BCIQ Company Profiles

Bayer AG